HER2 Breast Cancer Market

May 09, 2025

ENHERTU, a next-generation antibody-drug conjugate (ADC) jointly developed by Daiichi Sankyo/ AstraZeneca since March 2019, except in Japan, where Daiichi Sankyo maintains exclusive rights. It is worth noting that recently, in November 2024, Daiichi Sankyo and AstraZeneca were awarded the Galien Foundation 2024 Pri...

Aug 08, 2024

HR+/HER2- Breast Cancer is the most prevalent form of breast cancer. This type accounts for a higher percentage among all breast cancers. Hormone receptors are proteins that receive hormone signals and cue the cancer cells to grow. If breast cancer cells get signals from the hormone estrogen that could promote tumo...

Aug 08, 2024

More than a dozen companies have shifted their focus toward the development of HR-positive/HER2-negative breast cancer drugs. Some of them are Regor Therapeutics, Seagen Inc., CytomX Therapeutics, Taizhou EOC Pharma, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Daiichi Sankyo, Inc., Tyme, Inc., Seagen Inc.,...

Aug 08, 2024

Breast cancer is not a single disease leading to abnormal cell division in breast tissues. Breast cancer is the most common form of cancer in women. Each year, it affects over 2 million women globally and is the most significant cause of death among women.  According to DelveInsight’s estimates, there were aro...